Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Valent

Showing results (21-30 of 662) with videos related to

Pageof 67
Sort By:
American Journal of Hematology|November 6, 2023
Clinical impact of cytomorphology in mast cell leukemiaPeter Valent
Blood Reviews|February 28, 2009
Pathogenesis, classification, and therapy of eosinophilia and eosinophil disordersPeter Valent
British Journal of Haematology|June 11, 2008
Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the diseasePeter Valent
Blood|August 30, 2014
Targeting the JAK2-STAT5 pathway in CMLPeter Valent
Expert Review of Hematology|November 19, 2010
Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectivesMichel Arock, Peter Valent
Leukemia & Lymphoma|March 6, 2009
Update on genetic and molecular markers associated with myelodysplastic syndromesPeter Valent, Rotraud Wieser
Cell Cycle (Georgetown, Tex.)|February 15, 2014
BRD4: a BET(ter) target for the treatment of AML?Peter Valent, Johannes Zuber
Annals of Hematology|June 25, 2024
Stable responses to danicopan as add-on to ravulizumab in two patients with paroxysmal nocturnal hemoglobinuriaWolfgang Füreder, Peter Valent
The Journal of Allergy and Clinical Immunology. in Practice|April 10, 2019
Doctor, I Think I Am Suffering from MCAS: Differential Diagnosis and Separating Facts from FictionPeter Valent, Cem Akin
Leukemia & Lymphoma|June 4, 2011
Treatment of refractory or relapsed acquired aplastic anemia: review of established and experimental approachesWolfgang Füreder, Peter Valent
Pageof 67

Showing results (21-30 of 662) with videos related to

Sort By:
Pageof 67
American Journal of Hematology|November 6, 2023
Clinical impact of cytomorphology in mast cell leukemiaPeter Valent
Blood Reviews|February 28, 2009
Pathogenesis, classification, and therapy of eosinophilia and eosinophil disordersPeter Valent
British Journal of Haematology|June 11, 2008
Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the diseasePeter Valent
Blood|August 30, 2014
Targeting the JAK2-STAT5 pathway in CMLPeter Valent
Expert Review of Hematology|November 19, 2010
Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectivesMichel Arock, Peter Valent
Leukemia & Lymphoma|March 6, 2009
Update on genetic and molecular markers associated with myelodysplastic syndromesPeter Valent, Rotraud Wieser
Cell Cycle (Georgetown, Tex.)|February 15, 2014
BRD4: a BET(ter) target for the treatment of AML?Peter Valent, Johannes Zuber
Annals of Hematology|June 25, 2024
Stable responses to danicopan as add-on to ravulizumab in two patients with paroxysmal nocturnal hemoglobinuriaWolfgang Füreder, Peter Valent
The Journal of Allergy and Clinical Immunology. in Practice|April 10, 2019
Doctor, I Think I Am Suffering from MCAS: Differential Diagnosis and Separating Facts from FictionPeter Valent, Cem Akin
Leukemia & Lymphoma|June 4, 2011
Treatment of refractory or relapsed acquired aplastic anemia: review of established and experimental approachesWolfgang Füreder, Peter Valent
Pageof 67